PACTR202008836432905
Completed
Phase 1
A Phase I/II, Double-blind, Randomized, Active-controlled, Age De-escalation Trial to Assess Safety and Immunogenicity of a Measles Rubella Vaccine (MRV) Microneedle Patch (MRV-MNP) in Adults, MRV-primed Toddlers, and MRV-naïve Infants
ConditionsMeasles and Rubella
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Measles and Rubella
- Sponsor
- Micron Biomedical Inc
- Enrollment
- 285
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults: Be between 18 and 40 years inclusive on the day of consent.
- •Toddlers: Be between 15 and 18 months of age inclusive on the day of consent.
- •Infants: Be between 9 and 10 months of age inclusive on the day of consent.Be judged to be able to comprehend and comply with study requirement and procedures and must be willing and able to return for all scheduled follow\-up visits (adult cohort).
- •Have a parent who is judged to be able to comprehend and comply with study requirement and procedures and is willing and able to return for all scheduled follow\-up visits (toddler and infant cohort).
- •Be willing to avoid consumption (ingestion and topical application) of herbal or other local traditional medications throughout the course of the study.
- •Have a readily identifiable place of residence within a reasonable travelling distance of the clinical trial site.
- •Have a consistent means of telephone contact for the duration of trial participation
- •Have a site on one wrist that is judged to be suitable for MNP administration.
- •Adult female cohort only: have a negative serum pregnancy test at screening (V0\) and negative urine pregnancy test on the day of vaccination (V1\).
- •Adult female cohort only: employ an effective method of birth control for two months preceding and throughout the study
Exclusion Criteria
- •Have used any investigational product within the 90 days prior to study product administration or plan to use any investigational products during the period of study participation.
- •Have consumed (by ingestion or topical application) any herbal or other traditional medication within 14 days of study product administration
- •Have a history of serious reactions to any prior vaccination or known hypersensitivity to any component of the MRV\-MNP, MRV\-SC or PLA\-MNP including polyethylene foam with acrylic adhesive, silicone\-coated Kraft paper, stainless steel, and severe allergic reactions to cow's milk.
- •Have a history of anaphylactic shock or other life\-threatening allergic reactions
- •Have any chronic, clinically significant pulmonary, cardiovascular, hepatobiliary, gastrointestinal, renal, neurological, or haematological abnormality or illness that requires medical therapy.
- •Have a history of administration of any non\-study vaccines within the 56 days before the administration of study products or planned vaccination during study participation, except for non\-measles and rubella catch\-up/national campaign administered through the Gambian Ministry of Health.
- •Have a history of chronic administration (defined as more than 14 consecutive days) of immunosuppressant (\> 0\.5mg/kg/day of prednisolone or equivalent) or other immune modifying drugs within the 12 months prior to the administration of the study vaccine including the use of glucocorticoids. The use of inhaled/per nasal glucocorticoids will be permitted. The use of topical glucocorticoids within 12 months is not permitted.
- •Have a history of the administration of immunoglobulins and/or any blood products within the 12 months prior to administration of the study vaccine or anticipation of such administration during the study period.
- •Have a history of known disturbance of coagulation or blood disorder that could cause anaemia or excess bleeding (e.g. sickle cell disorders, thalassemia, and coagulation factor deficiencies).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase 2 study comparing INBRX-101 to plasma-derived A1PI therapy for AATD emphysemaAlpha-1 Antitrypsin Deficiency (AATD) EmphysemaMedDRA version: 23.1Level: LLTClassification code: 10001806Term: Alpha-1 anti-trypsin deficiency Class: 10010331Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]CTIS2023-508084-76-00Inhibrx Inc.94
Active, not recruiting
Phase 1
A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2018-001510-15-PLJanssen-Cilag International NV210
Active, not recruiting
Phase 1
A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2018-001510-15-DEJanssen-Cilag International NV210
Active, not recruiting
Phase 1
A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.CTIS2023-508458-25-00Hipra Scientific S.L.612
Active, not recruiting
Phase 1
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersEUCTR2017-004896-30-NLBristol-Myers Squibb International Corporation2,420